The Sage Group, Inc. provides transactional and strategic advice to healthcare and life science companies. It offers strategic assessment and planning, strategic analysis, valuations, mergers and acquisitions, corporate partnering/licensing, and new venture services. The company also provides licensing and partnering, divestment, buy-and sell-side, partnering and alliance development, product and technology corporate acquisition search, strategic assessment and planning, FDA regulatory advisory, due diligence, technology and molecule assessment, valuation, new ventures, interim management, deal negotiation and management, and market and customer research services. In addition, it facilitates...
3322 Route 22 West
Branchburg, NJ 08876
Founded in 1994
The Sage Group, Inc. Announces New Venture Capital Initiative - the $65 Million Joint Polish Investment Fund
Sep 28 14
The Sage Group announced that it is working with a team of investors and advisors to manage a new $65 million healthcare and life science fund. The Joint Polish Investment Fund (JPIF) is a closed Venture Capital Fund leveraged by additional €26 million in the form of a subordinated loan (€21 million) and a grant (€5 million) from the Polish government. An additional €12 million has also been committed by a strategic venture fund based in Warsaw, Adiuvo. The fund will invest in early as well as mid stage Life Science companies in Central and Eastern Europe with an investment holding period of 3-5 years. It will focus on areas with strong growth and high return potential like digital health, medical technology and nutraceuticals. The JPIF Fund will be managed by Dr. Orlowski and Kreske Nickelsen, an experienced venture fund manager with 16 years of experience in European Venture Capital including 3i and Aescap. She has managed funds, equity investments and partnering/business development projects in nearly all Western European countries. Kreske has broad experience from execution of over 60 transactions ranging from equity investments, licensing agreements, joint ventures to IPOs and trade sales.